On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

PreveCeutical Medical’s (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Breakthrough Sol-gel Drug Delivery Platform Featured in Proactive Investors Interview

  • PreveCeutical was recently featured in an interview by Proactive Investors
  • The company is currently developing its Sol-gel drug delivery platform for delivery of cannabinoids
  • Sol-gel technology is paving the way for direct nose-to-brain drug delivery

Innovative health sciences company PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) was recently featured by Proactive Investors in a “Corporate News Update” regarding the company’s potentially game-changing Sol-gel drug delivery platform (http://nnw.fm/TyU8k).  The company earlier provided a written press release updating the Sol-gel program (http://nnw.fm/86uqL).

Sol-gel, a nickname for soluble gel, is taken through nasal (systemic) administration and quickly gels once it comes in contact with the mucosal tissue, paving the way for direct nose-to-brain delivery of drugs and effectively bypassing the stomach and intestines. This eliminates first-pass metabolism and could dramatically enhance bioavailability – even in comparison with nasal sprays and other newer drug delivery systems. The gel stays in the nasal passages and slowly releases its drug formulation while keeping it active for up to seven days. These long-lasting effects, coupled with easy application, offer great attraction as a drug delivery vehicle for patients.

PreveCeutical’s breakthrough Sol-gel technology is currently being tested in connection with various cannabis strains for the development and eventual commercialization of cannabinoid-based Sol-gel products. The company’s Sol-gel research and development program uses five distinct Cannabis sativa L. strains that contain a broad array of CBD:THC concentrations, enabling the development of medical cannabis products designed to treat various ailments and diseases. PreveCeutical’s current focus for the Sol-gel program is on developing Sol-gel formulations that contain fixed CBD:THC concentrations that, when sprayed using a custom applicator, can consistently and safely deliver CBD:THC in predefined ratios to the central nervous system.

Prior to obtaining medicinal cannabis import permits and licenses, which PreveCeutical achieved earlier this year, the company laid the framework for its Sol-gel program by evaluating the non-cannabinoid elements of commercially sourced cannabis plants and assessing the viability of incorporating them into the Sol-gel delivery platform. Through this preliminary screening of non-cannabinoid elements, PreveCeutical gained increased understanding regarding how components (other than CBD and THC) affect the formulation of Sol-gel systems, along with insight into the chemical compatibility, physiochemical stability and biocompatibility of Sol-gels with biological membranes. This has paved the way for optimization of engineered Sol-gels that contain PreveCeutical’s target gelation and adherence properties.

Additionally, the company is in the process of developing a custom Sol-gel applicator. PreveCeutical’s research partner, The University of Queensland, has received multiple Sol-gel spray device prototypes from the company’s manufacturer. Evaluations are ongoing, but the preliminary results have been promising.

For more information, visit the company’s website at www.PreveCeutical.com

More from NetworkNewsWire

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Archives

Select A Month

NetworkNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 212.418.1217